Key Highlights

  • The company completed an IPO and concurrent private Placement with aggregate gross proceeds of about $602.5 million.
  • Net loss for the third quarter of 2026 was $28.1 million, compared with $17.9 million a year earlier.
  • Three Phase 2 trials of agazisiran for complement-mediated diseases are ongoing.
  • Onvuzosiran received FDA Fast Track Designation for hereditary angioedema.

ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) reported financial results for the third quarter ended September 30, 2026, and summarized recent Business developments on November 12, 2026. The San Diego company is developing next-generation siRNA therapeutics, including liver-targeted programs and candidates designed for delivery to tissues outside the liver. The quarter included the completion of an initial public offering and a concurrent private placement, which the company said will fund its clinical programs into 2030.

Financing and Cash Runway

ADARx completed its IPO and a concurrent private placement that generated aggregate gross proceeds of approximately $602.5 million. The company said its cash position is expected to fund operations into 2030. Chief Executive Zhen Li said the financings will support three clinical-stage programs running in parallel, two advanced preclinical candidates entering the clinic and additional IND filings.

The company's net loss for the quarter was $28.1 million, compared with $17.9 million for the same period of 2025. The release does not break out operating expenses by category in its summary, but the larger quarterly loss came during a period in which the company was preparing several programs for clinical work.

Agazisiran and Onvuzosiran Programs

Agazisiran is being studied in three Phase 2 trials for complement-mediated diseases. One trial covers renal diseases, including IgA nephropathy, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis. A second evaluates paroxysmal nocturnal hemoglobinuria, and a third looks at geographic atrophy secondary to age-related macular degeneration. ADARx said it intends to explore additional dosing regimens in its IgAN and PNH trials.

In August 2026, the U.S. Food and Drug Administration granted Fast Track designation to onvuzosiran for prophylaxis against attacks of hereditary angioedema. Onvuzosiran is being evaluated in the Phase 3 STOP-HAE trial. The company described the designation as part of its effort to advance programs with unmet medical needs.

Strategy and Pipeline Expansion

Zhen Li said the company sees a broad opportunity to expand the diseases its siRNA therapies can address, and that its liver-targeted programs and targeted delivery to extrahepatic tissues are central to that plan. The release describes these programs as differentiated, though it does not report clinical efficacy results from the trials in its summary.

The company said it plans additional IND filings as its pipeline expands. Timelines for those filings, and for the two preclinical candidates it intends to bring into the clinic, were not provided in the release.

Final Word

The third quarter shows ADARx completing a large financing and advancing several clinical programs, while its net loss rose from the prior-year period. The company's three Phase 2 agazisiran trials and the onvuzosiran Phase 3 study will determine the next stage of its pipeline. Its cash runway into 2030 gives the programs a defined funding period, and the trial readouts will indicate how the company's siRNA approach performs in patients.